SEC Form 4 · accession 0000904454-17-000529

Paratek Pharmaceuticals, Inc. · PRTK

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President, COO and CMO · Director

Period of report

Jul 19, 2017

Accepted (ET)

Jul 21, 2017 · 4:38 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001178711

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Jul 19, 2017	M	39,478	$4.30	A	147,910	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F2,F3,F4	$4.30	Jul 19, 2017	M	39,478	D	—	Jun 28, 2024	Common Stock	39,478	39,479	D

F1Shares of common stock acquired from the exercise of a stock option.
F2The Issuer entered into an Agreement and Plan of Merger and Reorganization, dated as of June 30, 2014 (the "Merger Agreement"), by and among the Issuer, Tigris Merger Sub, Inc., Tigris Acquisition Sub, LLC and a Delaware corporation then known as Paratek Pharmaceuticals, Inc. ("Old Paratek").
F3On June 29, 2014, the Reporting Person was granted an option to purchase 1,169,742 shares of the common stock of Old Paratek under Old Paratek's 2014 Equity Incentive Plan at a per share exercise of price of $0.29 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 78,957 shares of the Issuer's common stock at a per share exercise price of $4.30 upon closing of the merger. The option was previously reported on Form 4 filed on November 3, 2014.
F4The vesting schedule for this stock option is as follows: 1/48th (2.1%) of the option, or approximately 1,645 shares, vests and becomes exercisable on each of the 48 months commencing on January 1, 2015, subject generally to the Reporting Person's continued employment with the Issuer